BofA Securities Reiterates Underperform Rating on Sage Therapeutics (SAGE)
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $14.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
